A mouse study, published in Nature Communications, suggests that Fibroblast Growth Factor 21 (FGF21) signalling is essential for mediating the metabolic health and life span benefits linked to low protein diets.
Amolyt Pharma has announced its accepted abstracts that will be presented at the European Congress of Endocrinology (ECE 2022) and the Endocrine Society Meeting (ENDO 2022). The selection covers new data on treatments for rare endocrine diseases, including acromegaly and parathyroid disorders.
Data from a Finnish study, published in the European Journal of Preventive Cardiology, indicates that hormonal shifts are responsible for approximately 10% of the changes in cholesterol metabolism and cardiovascular disease risk that occur during menopause, and can be mitigated by HRT.
Sparrow Pharmaceuticals will be presenting novel pharmacological data on its candidates for treating corticosteroid excess on 24 May at the European Congress of Endocrinology (ECE 2022).
A new consensus statement, published in the British Journal of Sports Medicine and endorsed by the Royal Osteoporosis Society, advises on the value of physical activity for improving symptoms in osteoporosis patients.
According to a German study, published in Diabetes Metabolism Research and Reviews, adrenal gland volume tends to be larger in patients with type 2 diabetes, and may be a useful marker of metabolic function.
Portuguese research, presented at the European Congress on Obesity, indicates that women who conceive after bariatric surgery are more likely to have an underweight baby, and that they should wait at least two years to minimise these risks.